

RECEIVED  
CENTRAL FAX CENTERREMARKS

MAR 12 2007

Applicants add new claims 62-64. Support for these claims is found, for example, on page 13, line 19, to page 14, line 7, of the specification as filed. These claims depend from claim 38, which has been deemed allowed. Claims 44, 57, and 59 have been amended to remove the term doxepin, and claim 48 has been amended to correct a punctuation error. No new matter has been added by the present amendments.

As an initial matter, Applicants acknowledge that the Examiner has deemed claims 5-42 and 59-61 allowed.

*Rejections under §§ 102(b) and 103(a)*


Claims 1-4 and 43-58 stand rejected under 35 U.S.C. §§ 102(b) and 103(a) as being anticipated by, or obvious in view of, the International Journal of Dermatology (1999). Applicants have cancelled claims 1-4 and claim 43. Applicants have amended claims 44 and 57 to remove the term doxepin. Because the prior art does not teach the combination of a corticosteroid with any of the recited compounds, the amended claims are both novel and non-obvious in view of the prior art. Applicants reserve the option of pursuing cancelled claims and/or claims to a doxepin in a related application.

RECEIVED  
CENTRAL FAX CENTERCONCLUSIONS

MAR 12 2007

Applicants submit that the claims are in condition for allowance, and such action is respectfully requested. If there are any additional charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 3/12/07  
Michael J. Belliveau, Ph.D.  
Reg. No. 52,608

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045